News
Burrill & Company Announces Close of Burrill Brazil Fund I January 18, 2012 | Press Release
David Wetherell Joins Burrill & Company Venture Capital Group as Managing Director January 06, 2012 | Press Release
Global Financial Market Turmoil Overshadows Biotech Successes in 2011 January 03, 2012 | Press Release
See all News
Venture Capital
CardioKine develops pharmaceuticals for the treatment and prevention of heart failure and related cardiovascular indications. Their initial product, Lixivaptan, an electrolyte-sparing diuretic, was licensed from Wyeth.
Website: http://www.cardiokine.com/